A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Clinical trial NCT06241846 · RECRUITING

Trial details

NCT number: NCT06241846
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Start date: 2024-02-22
Primary completion: 2027-02-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.